首页 > 市场调查报告书 > 医疗设备

体外诊断

市场调查报告书

商品编码

1422702

血液筛检市场- 副产品（试剂和试剂盒[NAT、ELISA]、仪器）、技术（血清学/免疫测定、快速测试、蛋白质印迹测定、NGS）、最终用途（医院、血库、病理实验室） -全球预测, 2024-2032

Blood Screening Market - By Product (Reagents & Kits [NAT, ELISA], Instruments), Technology (Serology/Immunoassays, Rapid Test, Western Blot Assays, NGS), End-use (Hospitals, Blood Banks, Pathology Laboratories) - Global Forecast, 2024-2032

出版日期: 2023年12月07日 | 出版商:

Global Market Insights Inc. | 英文 280 Pages | 商品交期: 2-3个工作天内

价格

简介目录

由于医疗保健技术的进步以及人们对早期疾病检测重要性的认识不断提高，血液筛检市场预计在 2024 年至 2032 年间复合CAGR为 7.3%。血液筛检有助于识别各种医疗状况，包括传染病和遗传性疾病。根据世界卫生组织的数据，2022 年共有 130 万人死于结核病，使其成为仅次于 COVID-19 的全球第二大传染病。

控制和预防传染病爆发的持续努力导致人们更加关注血液筛检，将其作为公共卫生措施的重要组成部分。此外，血库和输血中心进行血液筛检以确保捐血安全的需求进一步刺激了市场成长。

血液筛检产业根据产品、技术、最终用途和地区进行细分。

由于检测血液样本中特定蛋白质的精确度和多功能性，蛋白质印迹分析领域预计将在 2024 年至 2032 年期间显着增长。该技术具有很高的灵敏度和准确性，使其在识别与传染病或其他医疗状况相关的各种抗体、抗原或特定蛋白质方面特别有效。它提供了有关血液样本中目标分子的存在和浓度的详细信息，使其成为诊断和监测爱滋病毒和某些类型癌症等疾病的宝贵工具。

病理实验室部门预计在预测期内产生可观的收入，这得益于进行全面和精确诊断测试的专业知识。这些实验室拥有专业设备和熟练的专业人员，确保了血液筛检结果的准确性和可靠性。此外，预防保健和常规健康检查的日益增长趋势增加了对病理实验室提供的血液筛检服务的需求。

受该地区不断增长的人口的青睐，亚太地区血液筛检产业规模预计将在 2024 年至 2032 年期间大幅成长。对加强医疗基础设施和采用先进医疗技术的承诺有助于在预防性医疗实践中更广泛地使用血液筛检。随着政府和医疗保健提供者越来越关注应对公共卫生挑战，亚太地区的血液筛检市场经历了强劲成长。

产业生态系统分析
产业影响力
- 成长动力
  - 传染病流行率不断上升
  - 血液筛检技术的进步
  - 不断增加的输血程序
- 产业陷阱与挑战
  - 先进技术成本高
  - 获得训练有素的专业人员的机会有限
成长潜力分析
监管环境
未来市场趋势
技术景观
定价分析
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司矩阵分析
公司市占率分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：血液筛检市场规模及预测：依产品分类，2018-2032 年

主要动向：按产品
试剂和试剂盒
- NAT 试剂和试剂盒
  - 酶和聚合酶
  - 标准和控制
  - 探针和引子
  - 缓衝液、核苷酸和溶液
  - 标记和检测试剂
- 酵素连结免疫吸附试验
  - 免疫吸附剂
  - 控制
  - 共轭物
  - 基材
  - 样品稀释液和清洗液
- 其他试剂和试剂盒
仪器

第 6 章：血液筛检市场规模与预测：按技术分类，2018-2032 年

主要动力向：靠技术
核酸检测
- 转录介导的扩增
- 实时定量PCR
血清学/免疫测定
- 化学发光免疫分析
- 萤光免疫分析
- 比色计免疫分析/ELISA
快速测试
蛋白质印迹分析
下一代定序

第 7 章：血液筛检市场规模与预测：依最终用途，2018-2032 年

主要动向：依最终用途
医院
血库
病理实验室

第 8 章：血液筛检市场规模及预测：按地区划分，2018-2032 年

主要动向：按地区
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 义大利
- 西班牙
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 沙乌地阿拉伯
- 南非
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

Abbott Laboratories
F. Hoffmann-La Roche Ltd.
Grifols, S.A.
Hologic, Inc.
QIAGEN N.V.
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.
Siemens Healthineers AG
Thermo Fisher Scientific, Inc.
SOFINA s.a (Biomerieux)
Danaher Corporation
Ortho-Clinical Diagnostics, Inc.
DiaSorin S.p.A.

简介目录

Product Code: 7618

Blood Screening Market is anticipated to register a CAGR of 7.3% between 2024 and 2032, owing to the advancements in healthcare technologies and increased awareness regarding the importance of early disease detection. Blood screening helps in identifying various medical conditions, including infectious diseases and genetic disorders. As per WHO, a total of 1.3 million people died from tuberculosis in 2022, making it the second leading infectious disease worldwide after COVID-19.

The ongoing efforts to control and prevent infectious outbreaks have led to an increased focus on blood screening as a vital component of public health initiatives. Additionally, the need for blood screening in blood banks and transfusion centers to ensure the safety of blood donations further stimulates market growth.

Blood screening industry is segmented based on product, technology, end-use, and region.

Western blot assay segment is slated to witness significant growth during 2024-2032, owing to the precision and versatility in detecting specific proteins within blood samples. This technique offers high sensitivity and accuracy, making it particularly effective in identifying various antibodies, antigens, or specific proteins associated with infectious diseases or other medical conditions. It provides detailed information about the presence and concentration of target molecules in a blood sample, making it an invaluable tool in the diagnosis and monitoring of diseases such as HIV and certain types of cancers.

Pathology laboratories segment is poised to generate notable revenues over the forecast period, favored by the expertise in conducting comprehensive and precise diagnostic tests. The accessibility of specialized equipment and skilled professionals in these laboratories ensures the accuracy and reliability of blood screening results. Additionally, the increasing trend toward preventive healthcare and routine health check-ups enhances the demand for blood screening services provided by pathology laboratories.

Asia Pacific blood screening industry size is anticipated to grow at a significant pace over 2024-2032, favored by the region's growing population. The commitment towards enhancing healthcare infrastructure and the adoption of advanced medical technologies contribute to the wider usage of blood screening in preventive healthcare practices. As governments and healthcare providers increasingly focus on addressing public health challenges, the blood screening market experiences robust growth in APAC.

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Base estimates & working
1.3 Data collection
1.4 Forecast calculations
1.5 Data validation
1.6 Data Sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Global blood screening market 360 degree synopsis, 2018 - 2032
- 2.1.1 Business trends
- 2.1.2 Regional trends
- 2.1.3 Product trends
- 2.1.4 Technology trends
- 2.1.5 End-use trends

Chapter 3 Blood Screening Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of infectious diseases
  - 3.2.1.2 Advancements in blood screening technology
  - 3.2.1.3 Growing blood transfusion procedures
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of advanced technologies
  - 3.2.2.2 Limited access to trained professionals
3.3 Growth potential analysis
- 3.3.1 By product
- 3.3.2 By technology
- 3.3.3 By end-use
3.4 Regulatory landscape
3.5 Future market trends
3.6 Technological landscape
3.7 Pricing analysis
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis, 2023
4.3 Company market share analysis, 2023
4.4 Competitive analysis of major market players, 2023
4.5 Competitive positioning matrix, 2023
4.6 Strategy dashboard, 2023

Chapter 5 Blood Screening Market Size and Forecast, By Product, 2018-2032 (USD Million)

5.1 Key trends, by product
5.2 Reagents & kits
- 5.2.1 NAT reagents & kits
  - 5.2.1.1 Enzymes & polymerases
  - 5.2.1.2 Standards & controls
  - 5.2.1.3 Probes & primers
  - 5.2.1.4 Buffer, nucleotides, and solutions
  - 5.2.1.5 Labelling & detection reagents
- 5.2.2 ELISA
  - 5.2.2.1 Immunosorbents
  - 5.2.2.2 Controls
  - 5.2.2.3 Conjugates
  - 5.2.2.4 Substrates
  - 5.2.2.5 Sample diluents & wash solutions
- 5.2.3 Other reagents & kits
5.3 Instruments

Chapter 6 Blood Screening Market Size and Forecast, By Technology, 2018-2032 (USD Million)

6.1 Key trends, by technology
6.2 Nucleic acid test
- 6.2.1 Transcription-mediated amplification
- 6.2.2 Real-time PCR
6.3 Serology/immunoassays
- 6.3.1 Chemiluminescence immunoassay
- 6.3.2 Fluoresecent immunoassays
- 6.3.3 Colorimeter immunoassays/ELISA
6.4 Rapid test
6.5 Western blot assays
6.6 Next generation sequencing

Chapter 7 Blood Screening Market Size and Forecast, By End-use, 2018-2032 (USD Million)

7.1 Key trends, by end-use
7.2 Hospitals
7.3 Blood banks
7.4 Pathology laboratories

Chapter 8 Blood Screening Market Size and Forecast, By Region, 2018-2032 (USD Million)

8.1 Key trends, by region
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East & Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East & Africa